Kekule Life Sciences Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Kekule Life Sciences Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $296.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kekule Life Sciences Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $296.6K Trade | TransData Nexus

Kekule Life Sciences Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $296.6K Total Trade · DGFT Verified

Kekule Life Sciences Limited is an Indian pharmaceutical exporter with a total trade value of $296.6K across 2 products in 2 therapeutic categories. Based on 12 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Irinotecan ($264.6K), Ifosfamide ($32.1K), .

Kekule Life Sciences Limited — Export Portfolio & Destination Treemap

Kekule Life Sciences Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Kekule Life Sciences Limited? — Company Overview & Market Position

Kekule Life Sciences Limited, established on August 20, 2013, is a public unlisted company headquartered in Hyderabad, Telangana, India. The company operates under the Corporate Identification Number (CIN) U74900TG2013PLC089588 and is registered with the Registrar of Companies, Hyderabad. As of December 21, 2025, Kekule Life Sciences reported an authorized capital of ₹10.00 crore and a paid-up capital of ₹8.00 crore. The company employs approximately 40 professionals.

Kekule Life Sciences specializes in the manufacturing of finished pharmaceutical formulations, focusing primarily on oncology products. Their product portfolio includes medications such as Irinotecan and Ifosfamide, which are integral to cancer treatment regimens. The company's manufacturing facilities are located at Plot No. 171 and 181, IDA, Kondapalli (V), Ibrahimpatnam, Krishna District, Andhra Pradesh.

What Does Kekule Life Sciences Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Irinotecan$264.6K 2

Product Portfolio — Top 2 by Export Value

Kekule Life Sciences Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Irinotecan	Oncology	$264.6K	9	0.6%	11
2	Ifosfamide	Advanced Oncology	$32.1K	3	1.3%	11

Kekule Life Sciences Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $296.6K. The top category is Oncology (89.2% of portfolio), followed by Advanced Oncology (10.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Kekule Life Sciences Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Kekule Life Sciences Limited operates a specialized manufacturing unit dedicated to oncology products, adhering to WHO-GMP standards. The facility is equipped with state-of-the-art infrastructure and production capabilities that meet international standards. This setup enables the company to offer a complete range of oncology products, including both sterile and non-sterile formulations, with comprehensive containment solutions.

3Key Leadership

The leadership team at Kekule Life Sciences Limited comprises:

Sridhar Vootla – Managing Director
Srilakshmi Kudaravalli – Director
Apparao Vootla – Director
Kudaravalli Raja Rao – Director
Kudaravalli Sridhar – Director

These individuals bring a wealth of experience and expertise to the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Kekule Life Sciences Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Kekule Life Sciences Limited's export activities, as per TransData Nexus proprietary trade data, include shipments of finished pharmaceutical formulations to various international markets. The company's top two exported products are Irinotecan and Ifosfamide, with a combined export value of $297,000 USD across 12 shipments. These products are primarily categorized under oncology and advanced oncology therapeutic areas. However, specific details regarding regulatory approvals, market access status, and filings in the US, EU, UK, Australia, and Japan are not available in the provided data.

2Emerging Markets

Kekule Life Sciences Limited's export data indicates a focus on oncology products, which are critical in emerging markets where cancer treatment options are expanding. The company's adherence to WHO-GMP standards positions it favorably for potential collaborations and market entry in regions such as Africa, Latin America, and Southeast Asia. While specific data on WHO prequalification or market penetration in these regions is not available, the company's product offerings align with the therapeutic needs of these markets.

3Geographic Strategy

Kekule Life Sciences Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Kekule Life Sciences Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not available in the provided data. Given the company's focus on oncology products, obtaining FDA approvals would be crucial for market access in the United States. It is recommended to consult the FDA's official database or contact the company directly for detailed regulatory status.

2WHO & EU GMP

Kekule Life Sciences Limited's manufacturing facility is WHO-GMP approved, indicating compliance with international standards for pharmaceutical manufacturing. However, specific information regarding EU GMP certification or EDQM status is not available in the provided data. Securing EU GMP certification would be essential for market access in European Union member states. Prospective partners and clients should verify the company's certification status through official channels.

3CDSCO & Indian Regulatory

Kekule Life Sciences Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Kekule Life Sciences Limited operates in the competitive oncology pharmaceutical market, focusing on products like Irinotecan and Ifosfamide. While specific market share data is not available, the company's specialization in oncology formulations positions it against other manufacturers in this niche. A detailed competitive analysis would require access to market research reports and competitor financials.

2Key Differentiators

Kekule Life Sciences Limited's key differentiators include its specialized focus on oncology products, adherence to WHO-GMP standards, and a manufacturing facility equipped with state-of-the-art infrastructure. These factors enable the company to offer high-quality, cost-competitive products with short development times, catering to the needs of the oncology market.

3Strategic Position

Kekule Life Sciences Limited's current strategic direction centers on the production of oncology pharmaceutical formulations. The company's adherence to WHO-GMP standards and its specialized manufacturing facility underscore its commitment to quality and compliance. Looking ahead, expanding the product portfolio to include other therapeutic areas and seeking additional regulatory approvals could enhance the company's market presence and growth prospects.

Buyer Due Diligence Brief — Evaluating Kekule Life Sciences Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Kekule Life Sciences Limited has demonstrated a consistent track record in exporting finished pharmaceutical formulations, with a total export value of $297,000 USD across 12 shipments. The company's focus on oncology products and adherence to international manufacturing standards indicate reliability and commitment to quality. Prospective clients should verify the company's certifications and regulatory approvals to ensure alignment with their requirements.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance and quality standards:

FDA Approval: Confirm the company's FDA facility registrations and approved ANDAs through the FDA's official database.

WHO-GMP Certification: Verify the WHO-GMP certification status of the manufacturing facility.

EU GMP Certification: Ensure the company holds EU GMP certification for market access in European Union member states.

Frequently Asked Questions — Kekule Life Sciences Limited

How many pharmaceutical products does Kekule Life Sciences Limited export from India?

Kekule Life Sciences Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Irinotecan ($264.6K), Ifosfamide ($32.1K). Total export value is $296.6K.

What is Kekule Life Sciences Limited's total pharmaceutical export value?

Kekule Life Sciences Limited's total pharmaceutical export value is $296.6K, based on 12 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Kekule Life Sciences Limited cover?

Kekule Life Sciences Limited exports across 2 therapeutic categories. The largest are Oncology (89.2%, 1 products), Advanced Oncology (10.8%, 1 products).

Get Full Kekule Life Sciences Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.